The Cold Chain Medicine Logistics segmentation by application is anchored in three primary sub‑markets: vaccines, biologics, and blood products. Vaccines dominate the landscape, accounting for roughly 45 % of total revenue, driven by global immunization programs and stringent temperature‑sensitivity requirements that demand continuous monitoring and rapid distribution. Biologics, representing about 35 % of the market, encompass monoclonal antibodies, gene‑therapy vectors, and recombinant proteins; their high unit value and complex storage conditions (‑70 °C to 2 °C) push logistics providers toward specialized insulated containers and real‑time data logging. Blood products—including plasma, platelets, and red cells—contribute the remaining 20 % and are characterized by short shelf‑life and strict regulatory oversight, which forces logistics operators to maintain dense regional hub networks and deploy temperature‑controlled vehicles with redundancy systems. Collectively, these application segments shape the overall market size by dictating infrastructure investment, technology adoption, and service‑level differentiation across the cold‑chain value chain.